Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 4/20 | 0.44 |
| ▸ | NOS2 | P35228 | 4/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | HEXA | P06865 | 3/20 | 0.37 |
| ▸ | HEXB | P07686 | 3/20 | 0.37 |
| ▸ | DHFR | P00374 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5650256 | 0.83 | NOS3 (0.35) | NOS3NOS2NOS1ALDH1A1HSD17B10 | |
| Hydrochloric Acid SCHEMBL7507774 | 0.81 | NOS3 (0.35) | NOS3NOS2NOS1ALDH1A1HSD17B10 | |
| SCHEMBL10392532 | 0.79 | NOS3 (0.39) | NOS3NOS2NOS1DHFRALDH1A1 | |
| SCHEMBL17229300 | 0.78 | NOS2 (0.42) | NOS3NOS2NOS1ALDH1A1HSD17B10 | |
| SCHEMBL25649283 | 0.76 | NOS3 (0.39) | NOS3NOS2NOS1HEXAHEXB | |
| SCHEMBL23937884 | 0.75 | NOS3 (0.34) | NOS3NOS2NOS1DHFRHSD17B10 | |
| SCHEMBL9753602 | 0.74 | NOS3 (0.44) | NOS3NOS2NOS1HEXAHEXB | |
| SCHEMBL28292898 | 0.74 | NOS3 (0.44) | NOS3NOS2NOS1HEXAHEXB | |
| SCHEMBL27454384 | 0.72 | CYP3A4 (0.43) | NOS3NOS2NOS1ALDH1A1KDM4E | |
| SCHEMBL2472952 | 0.71 | LMNA (0.39) | NOS3NOS2NOS1DHFRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695166-B2 | Pyrazolopyridine pyrazolopyrimidine and related compounds | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| WO-2015171527-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | TPMT, DPYD, XDH | NOS3 3599/4885NOS2 4129/4885NOS1 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.